Scarica l'app Stockscreener
6.735
4.87%
-0.345
Dopo l'orario di chiusura:
6.75
0.015
+0.22%
Precedente Chiudi:
$7.08
Aprire:
$7.12
Volume 24 ore:
52,712
Relative Volume:
0.34
Capitalizzazione di mercato:
$58.40M
Reddito:
$137.27M
Utile/perdita netta:
$-123.57M
Rapporto P/E:
-0.6151
EPS:
-10.95
Flusso di cassa netto:
$-102.89M
1 W Prestazione:
-12.30%
1M Prestazione:
+67.54%
6M Prestazione:
+5.73%
1 anno Prestazione:
-37.00%
Intervallo 1D:
$6.70
$7.17
Intervallo di 1 settimana:
$6.6386
$7.721
Portata 52W:
$3.51
$16.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Nome
Karyopharm Therapeutics Inc
Settore
Industria
Telefono
617-658-0600
Indirizzo
85 WELLS AVENUE, NEWTON, MA
Confronta KPTI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
6.735 | 58.79M | 137.27M | -123.57M | -102.89M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Ripresa | H.C. Wainwright | Buy |
| 2023-01-19 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Iniziato | Morgan Stanley | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-07-23 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-05 | Reiterato | Robert W. Baird | Outperform |
| 2019-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Reiterato | BofA/Merrill | Underperform |
| 2019-02-27 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Iniziato | B. Riley FBR | Buy |
| 2018-11-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-05-24 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-04-02 | Ripresa | Leerink Partners | Outperform |
| 2017-11-15 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2016-09-08 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-08-18 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-28 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Is Karyopharm Therapeutics Inc. gaining market shareCEO Change & Scalable Portfolio Growth Methods - khodrobank.com
Can Karyopharm Therapeutics Inc. recover in the next quarterInsider Buying & Real-Time Buy Signal Notifications - Newser
Analyzing recovery setups for Karyopharm Therapeutics Inc. investorsJuly 2025 Outlook & Technical Pattern Based Buy Signals - Newser
Published on: 2025-09-03 09:05:10 - Newser
Strategies to average down on Karyopharm Therapeutics Inc.July 2025 Earnings & Safe Swing Trade Setups - Newser
Will Karyopharm Therapeutics Inc. benefit from rate cutsJuly 2025 News Drivers & Comprehensive Market Scan Reports - khodrobank.com
What machine learning models say about Karyopharm Therapeutics Inc.Trade Exit Summary & Weekly High Potential Alerts - Newser
Is now the right time to enter Karyopharm Therapeutics Inc.Weekly Risk Report & Fast Gain Swing Alerts - khodrobank.com
How to use a screener to detect Karyopharm Therapeutics Inc. breakoutsStock Surge & Free Technical Confirmation Trade Alerts - Newser
Karyopharm Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Using data tools to time your Karyopharm Therapeutics Inc. exitForecast Cut & Stock Market Timing Techniques - Newser
Is Karyopharm Therapeutics Inc. benefiting from innovation trends2025 Volatility Report & Capital Protection Trading Alerts - خودرو بانک
What candlestick patterns are forming on Karyopharm Therapeutics Inc.Market Rally & AI Enhanced Execution Alerts - Newser
Karyopharm Therapeutics Inc. stock daily chart insightsQuarterly Market Review & Accurate Buy Signal Notifications - Newser
What high frequency data says about Karyopharm Therapeutics Inc.Weekly Stock Recap & Accurate Entry/Exit Alerts - Newser
Can you recover from losses in Karyopharm Therapeutics Inc.July 2025 EndofMonth & Accurate Entry/Exit Alerts - Newser
What are Karyopharm Therapeutics Inc.’s recent SEC filings showingPortfolio Growth Summary & Risk Adjusted Swing Trade Ideas - خودرو بانک
Analyzing Karyopharm Therapeutics Inc. with multi timeframe chartsQuarterly Growth Report & Accurate Trade Setup Notifications - Newser
How Karyopharm Therapeutics Inc. stock reacts to Fed policy changesBull Run & Real-Time Volume Spike Alerts - Newser
Published on: 2025-09-01 11:39:57 - beatles.ru
What momentum shifts mean for Karyopharm Therapeutics Inc.2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - Newser
Forecasting Karyopharm Therapeutics Inc. price range with options dataMarket Volume Report & High Accuracy Trade Signal Alerts - Newser
How to read the order book for Karyopharm Therapeutics Inc.Market Sentiment Report & Reliable Price Action Trade Plans - Newser
Will Karyopharm Therapeutics Inc. stock go up soon2025 Risk Factors & Low Risk High Reward Ideas - Newser
Can Karyopharm Therapeutics Inc. hit a new high this monthChart Signals & High Win Rate Trade Alerts - Newser
Trend analysis for Karyopharm Therapeutics Inc. this weekJuly 2025 Catalysts & Weekly Breakout Stock Alerts - Newser
Multi factor analysis applied to Karyopharm Therapeutics Inc.July 2025 Drop Watch & Daily Stock Trend Reports - Newser
Using AI based signals to follow Karyopharm Therapeutics Inc.Dividend Hike & Expert Approved Momentum Trade Ideas - Newser
Karyopharm Therapeutics Inc. stock prediction for this weekTrade Volume Report & Advanced Swing Trade Entry Plans - Newser
Is Karyopharm Therapeutics Inc. trending in predictive chart modelsPortfolio Gains Summary & Free Community Supported Trade Ideas - Newser
Is a relief rally coming for Karyopharm Therapeutics Inc. holdersPortfolio Risk Report & Safe Entry Trade Signal Reports - Newser
Using flow based indicators on Karyopharm Therapeutics Inc.July 2025 Rallies & Safe Capital Allocation Plans - Newser
Karyopharm Therapeutics Inc Azioni (KPTI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Karyopharm Therapeutics Inc Azioni (KPTI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Abate Kristin | Chief Accounting Officer |
Jul 22 '25 |
Sale |
4.00 |
238 |
952 |
9,475 |
| Paulson Richard A. | President and CEO |
May 06 '25 |
Sale |
7.12 |
236 |
1,680 |
82,503 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Apr 23 '25 |
Sale |
6.17 |
419 |
2,585 |
28,853 |
| Paulson Richard A. | President and CEO |
Apr 04 '25 |
Sale |
3.74 |
245 |
916 |
82,739 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Mar 04 '25 |
Sale |
6.29 |
3,445 |
21,669 |
34,314 |
| Paulson Richard A. | President and CEO |
Mar 04 '25 |
Sale |
6.29 |
11,694 |
73,555 |
82,984 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Mar 04 '25 |
Sale |
6.29 |
3,587 |
22,562 |
29,272 |
| Poulton Stuart | EVP, Chief Development Officer |
Mar 04 '25 |
Sale |
6.29 |
3,548 |
22,317 |
27,414 |
| Mano Michael | SVP, General Counsel&Secretary |
Mar 04 '25 |
Sale |
6.29 |
2,793 |
17,568 |
21,047 |
| Poulton Stuart | EVP, Chief Development Officer |
Feb 18 '25 |
Sale |
0.63 |
5,914 |
3,726 |
320,714 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):